@article{f06fcb179eb142a8abdc0197eb24fcd6,
title = "A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: Design and rationale",
abstract = "Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I-III clinical trials, including Phase III studies in non-small-cell lung cancer, ovarian cancer and breast cancer. Tumor cells with deleterious BRCA1 or BRCA2 mutations are deficient in homologous recombination DNA repair and are intrinsically sensitive to platinum therapy and poly(ADP-ribose) polymerase inhibitors. We describe herein the design and rationale of a Phase II trial investigating whether the addition of veliparib to temozolomide or carboplatin/paclitaxel provides clinical benefit over carboplatin/paclitaxel with placebo in patients with locally recurrent or metastatic breast cancer harboring a deleterious BRCA1 or BRCA2 germline mutation (Trial registration: EudraCT 2011-002913-12, NCT01506609).",
keywords = "BRCA1, BRCA2, DNA damage, PARP, PARP inhibitor, PARP trapping, breast cancer, synthetic lethality, veliparib",
author = "Isakoff, {Steven J.} and Shannon Puhalla and Domchek, {Susan M.} and Michael Friedlander and Bella Kaufman and Mark Robson and Telli, {Melinda L.} and V{\'e}ronique Di{\'e}ras and Han, {Hyo Sook} and Garber, {Judy E.} and Johnson, {Eric F.} and David Maag and Qin Qin and Giranda, {Vincent L.} and Shepherd, {Stacie P.}",
note = "Publisher Copyright: {\textcopyright} 2015 AbbVie Inc.",
year = "2017",
month = feb,
doi = "10.2217/fon-2016-0412",
language = "אנגלית",
volume = "13",
pages = "307--320",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Taylor and Francis Ltd.",
number = "4",
}
